Meflin confers antifibrotic properties to intestinal fibroblasts in inflammatory bowel disease
Authors:
- Jingxi MuJMJingxi Mu
- Keiko MaedaKMKeiko Maeda
- Tadashi IidaTITadashi Iida
- Shinji MiiSMShinji Mii
- Nobutoshi EsakiNENobutoshi Esaki
- Yukihiro ShirakiYSYukihiro Shiraki
- Yasuyuki MizutaniYMYasuyuki Mizutani
- Masanao NakamuraMNMasanao Nakamura
- Takeshi YamamuraTYTakeshi Yamamura
- Tsunaki SawadaTSTsunaki Sawada
- Eri IshikawaEIEri Ishikawa
- Kentaro MurateKMKentaro Murate
Open Access
- 19 May 2026
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (13)
Abstract
Dysfunctional intestinal fibrosis is an irreversible complication of Crohn’s disease (CD), The complex heterogeneity of intestinal mesenchymal cells makes it difficult to understand the pathogenesis of intestinal fibrosis. Previously, we identified Meflin as a marker of fibroblast subsets. This study aimed to explore the role of Meflin-positive fibroblasts in intestinal fibrogenesis and investigate the potential of pharmacological control of Meflin expression as a treatment for patients with CD. Our results indicated that Meflin expression was upregulated in fibroblasts at the early stage of fibrosis but was downregulated in established fibrosis in both patients with CD and two different mouse models, which are the chronic dextran sodium sulfate (DSS) model and an interleukin-10-deficient model that spontaneously develops intestinal inflammation. Meflin-deficient mice exacerbated intestinal fibrosis with dysregulated expression of non-canonical Wnt ligand WNT5A and its receptor ROR2. Pharmacologically induced Meflin expression through the administration of a synthetic retinoid reversed intestinal fibrosis in the DSS model and suppressed pro-fibrotic protein secretion in fibroblasts isolated from patients with CD. Our findings indicate that Meflin-positive fibroblasts represent a functional subpopulation that suppresses intestinal fibrosis. Augmentation of Meflin expression shows antifibrotic effects and holds promise as a therapeutic approach for intestinal fibrosis in patients with CD.Keywords
Funding Information
- Japan Science and Technology Agency (JPMJMS2214-11)
- Japan Science and Technology Agency (JPMJSP2125)
- Japan Society for the Promotion of Science (JP21K15995)
- Japan Society for the Promotion of Science (JP21K5920)
- Japan Society for the Promotion of Science (22H02848)
- Japan Society for the Promotion of Science (22K18390)
- Japan Agency for Medical Research and Development (JP24gm1210009)
- Japan Agency for Medical Research and Development (JP24ama221333)
- Takeda Science Foundation (NA)
- JSIBD Grants-in-Aid for IBD Research (NA)
- Japan Science and Technology Agency (JPMJFR245K)
- Japan Agency for Medical Research and Development (JP256f0137010)
This publication has 43 references indexed in Scilit:
- Spontaneous tumour regression in keratoacanthomas is driven by Wnt/retinoic acid signalling cross-talkNature Communications, 2014
- IL-10 Treatment Is Associated with Prohibitin Expression in the Crohn’s Disease Intestinal Fibrosis Mouse ModelMediators of Inflammation, 2013
- Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's DiseaseNew England Journal of Medicine, 2012
- Wnt5a Potentiates TGF-β Signaling to Promote Colonic Crypt Regeneration After Tissue InjuryScience, 2012
- Retinoic Acid–Induced Pancreatic Stellate Cell Quiescence Reduces Paracrine Wnt–β-Catenin Signaling to Slow Tumor ProgressionGastroenterology, 2011
- Proximal events in Wnt signal transductionNature Reviews Molecular Cell Biology, 2009
- Purified Wnt5a Protein Activates or Inhibits β-Catenin–TCF Signaling Depending on Receptor ContextPLOS Biology, 2006
- Interleukin-10 and the Interleukin-10 ReceptorAnnual Review of Immunology, 2001
- Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid.1997
- Interleukin-10-deficient mice develop chronic enterocolitisCell, 1993